Pay in 4 interest-free payments of $6.50 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
It cannot act on cells and tissues
But raw efficacy numbers do not tell the full story
At that point, pricing may reflect branded-drug rules, insurance coverage decisions, and standard prescribing channels instead of today's patchwork access situation
In the drugs best showing so far, the ATTAIN-1 trial, people taking orforglipron lost on average 12.4% of their baseline weight, a notch below the roughly 14% weight loss seen in similar trials of Novo Nordisks injectable Wegovy and also below the typical results seen with Eli Lillys tirzepatide, a dual GLP-1/GIP medication
doi: 10.1530/JOE-13-0414 100 ten KulveJSVeltmanDJvan BloemendaalLBarkhofFDrentMLDiamantMet al
The x(c)-cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases
US$ 22.82
US$ 27.82
US$ 29.00
US$ 21.84
US$ 21.21
US$ 26.65
US$ 23.39
US$ 20.71
